Advertisement

 

 

Natural occurrence of NS5B inhibitor resistance-associated variants in Brazilian patients infected with HCV or HCV and HIV.

Natural occurrence of NS5B inhibitor resistance-associated variants in Brazilian patients infected with HCV or HCV and HIV.
Author Information (click to view)

Noble CF, Malta F, Lisboa-Neto G, Gomes-Gouvêa MS, Leite AG, de Castro VF, Santana RA, Carrilho FJ, Mendes-Correa MC, Pinho JR,


Noble CF, Malta F, Lisboa-Neto G, Gomes-Gouvêa MS, Leite AG, de Castro VF, Santana RA, Carrilho FJ, Mendes-Correa MC, Pinho JR, (click to view)

Noble CF, Malta F, Lisboa-Neto G, Gomes-Gouvêa MS, Leite AG, de Castro VF, Santana RA, Carrilho FJ, Mendes-Correa MC, Pinho JR,

Advertisement
Share on FacebookTweet about this on TwitterShare on LinkedIn

Archives of virology 2016 Oct 4()

Abstract

Resistance-associated variants (RAVs) represent a challenge to the success of new HCV therapies. The aim of this study was to describe the prevalence of naturally occurring NS5B RAVs in Brazilian direct acting antivirals (DAA)-naïve patients infected with HCV genotype 1, or co-infected with HIV. Patient enrollment and sample collection were performed between 2011 and 2013. Using Sanger-based sequencing, 244 sequences were obtained. RAVs detected in HCV-1a sequences were V321A (1.6 %), M414V (1.3 %), A421V (21.4-23.7 %), A421G (1.3 %) and Y448H (1.3 %); and in HCV-1b sequences were L159F (16.1 %), C316N (7.1-16.3 %) and A421V (3.2-6.3 %). Understanding the real RAVs scenario in patients is fundamental to establishing the most effective therapeutic strategy and in minimizing the risks for their selection.

Submit a Comment

Your email address will not be published. Required fields are marked *

10 − one =

[ HIDE/SHOW ]